Trust, not sequencing capacity, is what constrains national genomics. Our answer is oversight that is independent, nationally led, technically enforced and published.
These are the commitments LydiaRx makes in every programme it works in. Each is enforced technically, institutionally, or both.
Governance documents are drafted to CIOMS, Declaration of Helsinki, UNESCO and GA4GH standards.
National majority. Decides every use of the data.
Oversees the governance standard, the audit programme and the ethics pathway.
Builds and operates the platform that enforces those decisions. It does not decide access.
Former Chief Executive of Our Future Health, the UK's largest health-research programme, built from a standing start to national scale. Oxford DPhil statistician; Chair of SNOMED International.
Director, Colorado Center for Personalized Medicine; led its 450,000-patient sequencing partnership with Regeneron. An authority on equitable genomics in non-European ancestry populations.
Managing Director, GetReal Institute; formerly Head of Health Data and Outcomes at the ABPI.
United Kingdom pharmaceutical physician, with former roles at Sobi, Novartis Gene Therapies and Akcea.
Plus at least 2 nationally based board members will be selected for each country a programme is running in.
The Charter, the consent model and the data-access rules are available to governments and ethics committees on request.